Ajanta Pharma Limited

NSE AJANTPHARM.NS

Ajanta Pharma Limited Return on Equity (ROE) for the year ending March 31, 2024: 22.88%

Ajanta Pharma Limited Return on Equity (ROE) is 22.88% for the year ending March 31, 2024, a 31.83% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Ajanta Pharma Limited Return on Equity (ROE) for the year ending March 31, 2023 was 17.35%, a -20.51% change year over year.
Ajanta Pharma Limited Return on Equity (ROE) for the year ending March 31, 2022 was 21.83%, a 0.02% change year over year.
Ajanta Pharma Limited Return on Equity (ROE) for the year ending March 31, 2021 was 21.83%, a 21.29% change year over year.
Ajanta Pharma Limited Return on Equity (ROE) for the year ending March 31, 2020 was 18.00%, a 4.41% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NSE: AJANTPHARM.NS

Ajanta Pharma Limited

CEO	Mr. Yogesh Mannalal Agrawal M.B.A
IPO Date	July 1, 2002
Location	India
Headquarters	Ajanta House
Employees	8,073
Sector	Health Care
Industries Pharmaceuticals

Description

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India.

Key trends

Past 5 years